Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l
about
CD4 immunophenotyping in HIV infection.Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia.Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy.Effect of early versus deferred antiretroviral therapy for HIV on survival.Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.Antiretroviral therapy in the clinicOlder HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study.HIV protease inhibitors and obesityInfluence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.Antiretroviral therapy: when to startFactors Associated with Timing of Initiation of Antiretroviral Therapy among HIV-1 Infected Adults in the Niger Delta Region of Nigeria.HIV-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) -Mediating Antibodies Decline while NK Cell Function Increases during Antiretroviral Therapy (ART).Actual medication pill burden and dosing frequency in HIV-infected patients with undetectable viral loads.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.Field evaluation of Calypte's AWARE blood serum plasma (BSP) and oral mucosal transudate (OMT) rapid tests for detecting antibodies to HIV-1 and 2 in plasma and oral fluid.Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators.Saquinavir, the pioneer antiretroviral protease inhibitor.Health care access and health behaviors among men who have sex with men: the cost of health disparities.Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada.Efficacy, safety, and tolerability of long-term combination antiretroviral therapy in asymptomatic treatment-naïve adults with early HIV infection.Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003.Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.Comparing total health care costs and treatment patterns of HIV patients in a managed care setting.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).
P2860
Q30372724-EC8F1423-1C0F-4396-822F-33F52DFE0DDFQ33363196-B16C1AE6-28D2-44C4-BCD2-C80FA38405DEQ33511372-99A60D4E-44DD-4F67-93EA-EED6A4AFD907Q33789114-81D38E08-D771-4789-BB1F-592A82A1BAC0Q33790033-51293BC2-BEA0-4E91-A4EF-8790AC511427Q33877347-7B320719-DCF7-4728-94DD-DF84DB20F858Q34691316-24BBCEC0-0179-457D-9218-250ABEF43D11Q34792983-71D17C9F-137C-44A5-956D-A4C253BDE343Q35070832-C79F08D4-21E6-453C-B1C5-A80144D644DAQ35204279-9C5D5B2F-AAAE-4A31-AD8E-9FAF49818E0EQ35560631-FF069AA4-CB26-4CA8-9A19-0695B18F24C6Q35876207-4CFF3668-962D-4FEA-AFBB-5D41AAC7FA9CQ35878022-B4C7FBBD-9C0F-4C4D-BB28-8401AF9F5328Q36653838-142CE93C-EFE3-4D5F-97B3-3405E630B6C0Q37178883-A2910947-10E2-4041-87E3-3D5908B2DBD4Q37225453-28710735-FFC2-47BC-9582-88341A593E78Q37354933-803DB835-FFC6-4D97-8D08-252991F44F8FQ37593552-DB507B1B-BB7A-4115-B11A-D4B6444A7551Q40030556-D7AB4E57-8459-445B-9F37-76E33D1E29A8Q42250867-E4A55D25-3809-4BD0-AD4F-9740AF966C4BQ42635373-239226D0-0EB0-41A9-ABC4-717C3F0BFD70Q44128541-29675EE7-4C8F-4847-8B67-076398D26861Q44662445-2191427A-05BD-49E5-97F6-686FBC7E65C2Q46052493-5DBB5F57-8FD2-4A3B-A726-DD80CAA04F9BQ53851252-6652FFC8-2EBB-4D41-89E1-CD0DAA2AEA40
P2860
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@ast
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@en
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@en-gb
type
label
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@ast
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@en
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@en-gb
prefLabel
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@ast
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@en
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@en-gb
P2093
P50
P1433
P1476
Clinical efficacy of early ini ...... d CD4 cell count > 350 × 106/l
@en
P2093
Alexander Imhof
Fabian Meienberg
Martin Rickenbach
Milos Opravil
Rainer Weber
Serge Gallant
Thomas Wagels
P304
P356
10.1097/00002030-200207050-00009
P407
P577
2002-07-01T00:00:00Z